體內(nèi)PD-L1阻斷

(in vivo PD-L1 blockade)

1. Grasselly, C., et al. (2018). 'The Antitumor Activity of Combinations of Cytotoxic 

Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent' Front 

Immunol 9: 2100.

2. Stathopoulou, C., et al. (2018). 'PD-1 Inhibitory Receptor Downregulates Asparaginyl 

Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory 

T Cells' Immunity 49(2): 247-263 e247.

3. Jaworska, K., et al. (2015). 'Both PD-1 ligands protect the kidney from ischemia 

reperfusion injury' J Immunol 194(1): 325-333.

4. Kim, J., et al. (2015). 'Memory programming in CD8(+) T-cell differentiation is 

intrinsic and is not determined by CD4 help' Nat Commun 6: 7994.

5. Zander, R. A., et al. (2015). 'PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk 

Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity' Cell 

Host Microbe 17(5): 628-641.

體內(nèi)PD-L1阻斷，免疫熒光

(in vivo PD-L1 blockade, 

Immunofluorescence)

1.Willimsky, G., et al. (2013). 'Virus-induced hepatocellular carcinomas cause 

antigen-specific local tolerance' J Clin Invest 123(3): 1032-1043.